Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Classic homocystinuria is an autosomal recessive disorder caused by biallelic pathogenic variants in cystathionine beta-synthase (CBS), leading to deficient conversion of homocysteine to cystathionine. Affected individuals present with ectopia lentis, intellectual disability, skeletal abnormalities and a high risk of thromboembolism (HP:0001083, HP:0001249, HP:0002156, HP:0000924, HP:0001907). The biochemical hallmark is markedly elevated plasma homocysteine, which may be responsive to pyridoxine (vitamin B6) in a subset of patients.
Inheritance is autosomal recessive. A study of 24 Saudi Arabian patients found that 19 had one or more affected relatives, confirming familial segregation and supporting AR transmission ([PMID:17341972]). More than 268 unrelated probands have been reported worldwide, with consistent segregation in over 50 families ([PMID:14722927]).
The variant spectrum exceeds 130 distinct mutations, predominantly missense changes but also including frameshift, splice-site, and exon-deletion alleles. The canonical I278T (c.833T>C (p.Ile278Thr)) variant accounts for approximately 41% of alleles in pyridoxine-responsive patients ([PMID:7611293]). Founder alleles such as G307S are prevalent in Celtic populations, while population-specific alleles (e.g., p.Arg336Cys in Qatar) reflect geographic diversity.
Functional assays demonstrate that many missense mutations destabilize CBS or impair cofactor binding. Yeast complementation shows five of six tested variants lack activity under low pyridoxine, but R266K retains function in high-vitamin conditions, mirroring clinical responsiveness ([PMID:9361025]). In vitro studies reveal defective heme binding and aggregation for several pathogenic subunits, supporting a loss-of-function mechanism.
Animal models corroborate pathogenicity: Cbs−/− mice expressing human I278T or I278T/T424N survive neonatal lethality despite hyperhomocysteinemia, indicating non-enzymatic roles for CBS protein ([PMID:15972722]). Treatment of I278T and S466L mouse models with proteasome inhibitors restores mutant protein levels and lowers plasma homocysteine, illustrating potential therapeutic avenues ([PMID:23592311]).
Newborn screening by tandem mass spectrometry of total homocysteine from dried blood spots identified 14 Qatari cases (incidence ~1:1,800), whereas methionine alone would miss half of the patients, underscoring the need for homocysteine-based assays ([PMID:19914636]). Early diagnosis enables tailored therapy, including pyridoxine, dietary methionine restriction, and betaine supplementation.
Integration of extensive genetic and functional data establishes CBS-related homocystinuria as a definitive gene-disease association. Clinical utility spans diagnostic confirmation, family screening, newborn screening optimization, and potential small-molecule rescue. Key take-home: genotyping of CBS informs prognosis and guides personalized management, especially regarding vitamin responsiveness and thromboembolic risk.
Gene–Disease AssociationDefinitiveOver 268 unrelated probands across >50 families with consistent segregation and concordant functional data Genetic EvidenceStrong268 probands, familial segregation in 19 patients and multicentric cohorts reaching genetic evidence cap Functional EvidenceModerateYeast and in vitro assays demonstrate loss of activity for multiple missense variants; animal models and rescue studies confirm pathogenicity |